cdmedics: where are we ?
DESCRIPTION
CDMedics: where are we ?. Situation and future developments MEDICEL Meeting MALTA 08.09.11. CD-MEDICS Overall Objectives. Development of disposable microchip for screening of coeliac disease in a portable/hand-held device carrying out multi-analyte tests - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/1.jpg)
Situation and future developments
MEDICEL MeetingMALTA 08.09.11
![Page 2: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/2.jpg)
• Development of disposable microchip for screening of coeliac disease in a portable/hand-held device carrying out multi-analyte tests
• Simultaneous detection of coeliac disease associated autoantibodies (DPG and tissue transglutaminase) and HLA-DQ2 and DQ8 genes.
• The device will have embedded communication abilities for result storage and easy follow-up, management and monitoring of the patient’s response to withdrawal of gluten from the diet.
MEDICEL 2Malta 2011
![Page 3: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/3.jpg)
• Serology– Total IgA, DPG IgG and tTG IgA
• common dilution factor 1:100
• HLA Typing– Alleles
• DQA1*0501 / DQA1*0505
• DQB1*0201 / 0202
• DQB1*0302
– Genotypes• DQ2, DQ8
MEDICEL 3Malta 2011
![Page 4: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/4.jpg)
MEDICEL 4Malta 2011
![Page 5: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/5.jpg)
MEDICEL 5Malta 2011
![Page 6: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/6.jpg)
MEDICEL 6Malta 2011
![Page 7: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/7.jpg)
MEDICEL 7Malta 2011
![Page 8: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/8.jpg)
MEDICEL 8Malta 2011
![Page 9: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/9.jpg)
MEDICEL 9Malta 2011
![Page 10: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/10.jpg)
MEDICEL 10Malta 2011
![Page 11: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/11.jpg)
MEDICEL 11Malta 2011
![Page 12: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/12.jpg)
MEDICEL 12Malta 2011
![Page 13: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/13.jpg)
MEDICEL 13Malta 2011
Hospital Information System
Hospital Information System
Physician’s office
Physician’s office CDMEDICS
InstrumentCDMEDICS Instrument
Demographics Requests/ Replies
Patient / Test information
Patient’s data
![Page 14: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/14.jpg)
• Prototypes of instrumentation: available and tested
• Serology: reagents and prototypes tested
• HLA: reagents and prototypes tested.
MEDICEL 14Malta 2011
![Page 15: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/15.jpg)
• End of the project: June 2012• Instrumentation: final prototype and product line defined• Serology: final reagents within Jan 2012• HLA: final reagents within Jan 2012
• Industrial production: 2013
MEDICEL 15Malta 2011
![Page 16: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/16.jpg)
• Population based screening, and/or screening of high-risk groups and based on the data regarding HLA status, design individually tailored dietary options.
• Monitoring for adherence to the appropriate gluten-free diet either at their GP’s office, or from their own home, with data being communicated directly to their electronic medical record.
• Neonatal screening in risk groups to identify newborns who may develop coeliac disease.
16MEDICEL Malta 2011
![Page 17: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/17.jpg)
![Page 18: CDMedics: where are we ?](https://reader035.vdocuments.us/reader035/viewer/2022062717/56812b32550346895d8f3a43/html5/thumbnails/18.jpg)